Researchers are working on an “on and off” switch to improve the safety and efficacy of chimeric antigen receptor (CAR) T-cell therapy and counter the treatment’s potential negative effects, according to a Notre Dame press release. CAR T-cell therapy, which has been hailed as the “fifth pillar” of cancer treatment, is a novel treatment method that...Continue Reading

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses eligibly criteria for patients with multiple myeloma to receive chimeric antigen receptor (CAR) T-cell therapy. There have been very promising data published recently on the use of CAR T-cell therapy for patients with myeloma, says Madduri. The anti-BCMA CAR T-cell therapy bb2121 was granted a breakthrough...Continue Reading